Extensive coronary artery calcification (CAC) is common in people on hemodialysis. Sevelamer, a phosphate binder that does not contain calcium, is associated with slower progression of CAC than ...

The treatment of hyperphosphatemia was intensified by the additional mealtime administration of phosphate binders, such as aluminium hydroxide and calcium carbonate. Phosphate accumulation was ...

Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

A change in Medicare coverage for some dialysis medications has left nursing homes and their patients receiving in-house treatment for kidney failure in a serious bind.

Engaging patients in discussions about different phosphate binders and their unique characteristics is key to improving adherence and satisfaction. New therapies that reduce pill size or burden while ...

The review highlights the challenges faced by patients regarding current phosphate binders, particularly focusing on issues like high pill burdens and gastrointestinal side effects, which ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

(MENAFN- GlobeNewsWire - Nasdaq) Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence LOS ALTOS, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a ...